


Amendments to the Claims:

Claims 1-12 (cancelled)


13. (New) A compound of the formula



wherein:

one of X_1 and X_2 is nitrogen and the other is carbon, wherein each carbon atom of the heteroaryl rings is optionally substituted with a substituent selected from the group consisting of halogen, hydroxyl, alkoxy, CF_3 , alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkaryl, arylalkyl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, amino, alkylamino, dialkylamino, carboxylic acid, carboxylic ester, carboxamide, nitro, cyano, azide, alkylcarbonyl, acyl, and trialkylammonium;


A is selected from the group consisting of:




wherein n is 1-8; X_3 is O, S, SO_2 , or NR_1 ; and R_1 is selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, acyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, and dialkylaminocarbonyl;

the dashed lines indicate the presence of optional double bonds;


L is the point of bonding of A to the compound structure; and pharmaceutically acceptable salts thereof.



14. (New) The compound of Claim 13, wherein A is



15. (New) The compound of Claim 14, wherein X_3 is S or NR₁.



16. (New) The compound of Claim 13, wherein A is


17. (New) The compound of Claim 13, wherein A is , wherein n is 1-4.

18. (New) The compound of Claim 13, wherein X₁ is nitrogen.

19. (New) The compound of Claim 13, wherein X₂ is nitrogen.

20. (New) The compound of Claim 13, wherein the optional double bonds are present.

21. (New) The compound of Claim 13, having the formula



wherein:

X_4 is NR_1 ;

R_1 is selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, acyl, alkoxy carbonyl, aminocarbonyl, alkylaminocarbonyl and dialkylaminocarbonyl;

each carbon atom of the heteroaryl rings is optionally substituted with a substituent selected from the group consisting of halogen, hydroxyl, alkoxy, CF_3 , alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkaryl, arylalkyl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, amino, alkylamino, dialkylamino, carboxylic acid, carboxylic ester, carboxamide, nitro, cyano, azide, alkylcarbonyl, acyl, and trialkylammonium;

and pharmaceutically acceptable salts thereof.


22. (New) The compound of Claim 13, selected from the group consisting of 3,5-Bis-(2-pyridinylidene)-piperidin-4-one, 3,5-Bis-(2-pyridinylidene)-1-methylpiperidin-4-one, and 3,5-Bis-(4-pyridinylidene)-1-methylpiperidin-4-one.

23. (New) A pharmaceutical formulation, comprising a compound of Claim 13 and a pharmaceutically acceptable carrier.

24. (New) A pharmaceutical formulation, comprising a compound of Claim 21 and a pharmaceutically acceptable carrier.

25. (New) A pharmaceutical formulation, comprising a compound of Claim 22 and a pharmaceutically acceptable carrier.


26. (New) A method of treating cancerous tissue in a subject, comprising administering to the subject an effective amount of a compound of formula



wherein:

one of X₁ and X₂ is nitrogen and the other is carbon, wherein each carbon atom of the heteroaryl rings is optionally substituted with a substituent selected from the group consisting of halogen, hydroxyl, alkoxy, CF₃, alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkaryl, arylalkyl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, amino, alkylamino, dialkylamino, carboxylic acid, carboxylic ester, carboxamide, nitro, cyano, azide, alkylcarbonyl, acyl, and trialkylammonium;

A is selected from the group consisting of:




wherein n is 1-8; X₃ is O, S, SO, SO₂, or NR₁; and R₁ is selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, acyl, alkoxy carbonyl, aminocarbonyl, alkylaminocarbonyl, and dialkylaminocarbonyl;


the dashed lines indicate the presence of optional double bonds;

L is the point of bonding of A to the compound structure; and


pharmaceutically acceptable salts thereof.



27. (New) The method of Claim 26, wherein A is



28. (New) The method of Claim 27, wherein X₃ is S or NR₁.




29. (New) The method of Claim 26, wherein A is

31. (New) The method of Claim 26, wherein X₁ is nitrogen.

32. (New) The method of Claim 26, wherein X₂ is nitrogen.

33. (New) The method of Claim 26, wherein the optional double bonds are present.

34. (New) The method of Claim 26, wherein the compound has the formula



wherein:

X_4 is NR_1 ;

R_1 is selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, acyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl and dialkylaminocarbonyl; each carbon atom of the heteroaryl rings is optionally substituted with a substituent selected from the group consisting of halogen, hydroxyl, alkoxy, CF_3 , alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkaryl, arylalkyl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, amino, alkylamino, dialkylamino, carboxylic acid, carboxylic ester, carboxamide, nitro, cyano, azide, alkylcarbonyl, acyl, and trialkylammonium; and pharmaceutically acceptable salts thereof.

35. (New) The method of Claim 26, wherein the compound is selected from the group consisting of 3,5-Bis-(2-pyridinylidene)-piperidin-4-one, 3,5-Bis-(2-pyridinylidene)-1-methylpiperidin-4-one, and 3,5-Bis-(4-pyridinylidene)-1-methylpiperidin-4-one.

36. (New) A method of Claim 26, wherein the effective amount comprises an amount sufficient to inhibit VEGF production in the cancerous tissue.

37. (New) A method of Claim 26, wherein the effective amount comprises an amount sufficient to inhibit TF production in the cancerous tissue.

Appl. No.: 10/690,462
Filed: October 21, 2003
Page 8

38. (New) A method of Claim 26, wherein said administering step comprises administering an effective amount of the compound in a pharmaceutically acceptable carrier.